BR0210630A - Sistema fornecedor de liberação prolongada - Google Patents
Sistema fornecedor de liberação prolongadaInfo
- Publication number
- BR0210630A BR0210630A BR0210630-2A BR0210630A BR0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A
- Authority
- BR
- Brazil
- Prior art keywords
- implant
- tablet
- extended release
- release
- mini
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 4
- 239000007943 implant Substances 0.000 abstract 5
- 239000003826 tablet Substances 0.000 abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 239000008185 minitablet Substances 0.000 abstract 2
- 230000036765 blood level Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR6024A AUPR602401A0 (en) | 2001-06-29 | 2001-06-29 | Sustained release delivery system |
| PCT/AU2002/000866 WO2003009833A1 (en) | 2001-06-29 | 2002-07-01 | Sustained release delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210630A true BR0210630A (pt) | 2004-07-27 |
Family
ID=3829990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210630-2A BR0210630A (pt) | 2001-06-29 | 2002-07-01 | Sistema fornecedor de liberação prolongada |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8197839B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1411905A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4913321B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1536988A (cg-RX-API-DMAC7.html) |
| AU (2) | AUPR602401A0 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0210630A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2452075C (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ529858A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003009833A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| NZ530550A (en) * | 2001-09-11 | 2004-11-26 | Smart Drug Systems Inc | Preparation of sustained release pharmaceutical composition |
| PL1696822T3 (pl) * | 2003-11-13 | 2010-08-31 | Psivida Inc | Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną |
| BRPI0511694A (pt) * | 2004-05-31 | 2008-01-08 | Smart Drug Systems Inc | composições de liberação controlada |
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| WO2007123511A2 (en) * | 2006-03-24 | 2007-11-01 | Infinity Pharmaceuticals, Inc. | Dosing regimens for the treatment of cancer |
| US20090005869A1 (en) * | 2006-12-15 | 2009-01-01 | University Of Virginia Patent Foundation | Device which Attaches into a Joint and Carries a Payload of Controlled Release Drugs and Related Method thereof |
| NZ552290A (en) * | 2006-12-21 | 2009-05-31 | Bomac Research Ltd | Tablet fomulation |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| WO2009086451A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
| US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| JP2011522773A (ja) * | 2007-12-27 | 2011-08-04 | インフィニティ ファーマスーティカルズ、インク. | 治療剤での癌の処置方法 |
| US9005649B2 (en) | 2009-07-14 | 2015-04-14 | Board Of Regents, The University Of Texas System | Methods for making controlled delivery devices having zero order kinetics |
| CA2769795C (en) | 2009-08-05 | 2020-01-07 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
| WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| ITTO20111188A1 (it) | 2011-12-22 | 2013-06-23 | Vhit Spa | Pompa a cilindrata variabile e metodo di regolazione della sua cilindrata |
| WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| FI20155779A7 (fi) * | 2015-10-30 | 2017-05-01 | Solani Therapeutics Ltd | Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| CA3087238A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| CN111989068B (zh) | 2018-05-24 | 2024-10-25 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| CN110559431B (zh) * | 2019-10-11 | 2023-02-28 | 南京农业大学 | 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用 |
| JP2023509981A (ja) * | 2020-01-10 | 2023-03-10 | エキリーブル バイオファーマシューティカルズ べスローテン フェンノートシャップ | アベルメクチンによる神経障害の治療 |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| CN116687882A (zh) * | 2023-07-06 | 2023-09-05 | 杭州高成生物营养技术有限公司 | 一种布洛芬缓释小丸及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4331652A (en) * | 1979-09-12 | 1982-05-25 | Eli Lilly And Company | Controlled release parasitic formulations and method |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| DE3681348D1 (de) * | 1985-06-11 | 1991-10-17 | Teijin Ltd | Oral-arzneizubereitung mit retardwirkung. |
| SE444801B (sv) | 1985-06-28 | 1986-05-12 | Johan Magnus Ullman | Fender |
| US4786501A (en) * | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
| JPH01500899A (ja) * | 1986-05-16 | 1989-03-30 | ザ・ステイト・オブ・ビクトリア | 生物適合性インプラント |
| US5342622A (en) * | 1986-05-16 | 1994-08-30 | The State Of Victoria | Subdermal biocompatible implants |
| US5028430A (en) * | 1987-05-08 | 1991-07-02 | Syntex (U.S.A.) Inc. | Delivery systems for the controlled administration of LHRH analogs |
| US5035891A (en) * | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
| JPH0618958B2 (ja) * | 1989-03-08 | 1994-03-16 | 株式会社クラレ | 多層容器および包装体 |
| ATE90203T1 (de) | 1989-03-17 | 1993-06-15 | Pitman Moore Inc | Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen. |
| ES2058923T3 (es) | 1989-06-21 | 1994-11-01 | Univ Brown Res Found | Sistema para terapia neurologica. |
| US5091185A (en) | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
| JPH11508224A (ja) * | 1990-08-09 | 1999-07-21 | エンドコン・インコーポレーテッド | 多重ドラッグデリバリーシステム |
| NZ239370A (en) * | 1990-08-22 | 1994-04-27 | Merck & Co Inc | Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone |
| IS3778A7 (is) * | 1990-10-31 | 1992-05-02 | Amgen Inc. | Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt |
| US5211951A (en) * | 1991-07-24 | 1993-05-18 | Merck & Co., Inc. | Process for the manufacture of bioerodible poly (orthoester)s and polyacetals |
| JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
| JP3720386B2 (ja) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | 薬物放出制御製剤 |
| KR100210509B1 (ko) * | 1996-01-10 | 1999-07-15 | 성재갑 | 지속성 동물 성장 호르몬 제형 및 이의 제조 방법 |
| FR2745180B1 (fr) * | 1996-02-23 | 1998-05-07 | Dow Corning Sa | Procede de fabrication de dispositifs a liberation controlee |
| EP1014970A1 (en) * | 1997-09-23 | 2000-07-05 | Pfizer Limited | Parasiticidal formulations |
| AUPP279698A0 (en) | 1998-04-03 | 1998-04-30 | Sunscape Developments Limited | Sustained release formulation |
| WO2000003660A1 (en) | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| WO2000013666A1 (en) | 1998-09-05 | 2000-03-16 | Seung Jin Lee | Biodegradable particulate polymeric preparation and process for producing thereof |
| TWI246928B (en) * | 1998-09-10 | 2006-01-11 | Sumitomo Pharma | Long time drug-sustained release preparation |
| US6645192B2 (en) | 1998-09-30 | 2003-11-11 | Ivy Animal Health, Inc. | Pellet implant system for immediate and delayed release of antiparasitic drug |
| AU6283299A (en) | 1998-10-01 | 2000-04-17 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
| CA2379909C (en) | 1999-08-06 | 2011-01-04 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
| JP4230621B2 (ja) | 1999-08-12 | 2009-02-25 | 住友ゴム工業株式会社 | 空気入りタイヤ |
| JP4757995B2 (ja) * | 1999-11-10 | 2011-08-24 | 大日本住友製薬株式会社 | 薬物放出製剤 |
| TW524696B (en) * | 1999-11-10 | 2003-03-21 | Sumitomo Pharma | Sustained-release drug formulations |
| WO2001037811A1 (en) * | 1999-11-22 | 2001-05-31 | Akzo Nobel N.V. | Composition allowing predefined and controlled release of active ingredient, preparation thereof and use |
| US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| JP4504122B2 (ja) | 2004-07-02 | 2010-07-14 | 株式会社マキタ | 生垣バリカン |
-
2001
- 2001-06-29 AU AUPR6024A patent/AUPR602401A0/en not_active Abandoned
-
2002
- 2002-07-01 NZ NZ529858A patent/NZ529858A/en not_active IP Right Cessation
- 2002-07-01 CA CA2452075A patent/CA2452075C/en not_active Expired - Fee Related
- 2002-07-01 US US10/482,335 patent/US8197839B2/en active Active
- 2002-07-01 EP EP02742516A patent/EP1411905A4/en not_active Withdrawn
- 2002-07-01 BR BR0210630-2A patent/BR0210630A/pt not_active IP Right Cessation
- 2002-07-01 AU AU2002344686A patent/AU2002344686B2/en not_active Expired
- 2002-07-01 JP JP2003515226A patent/JP4913321B2/ja not_active Expired - Fee Related
- 2002-07-01 WO PCT/AU2002/000866 patent/WO2003009833A1/en not_active Ceased
- 2002-07-01 CN CNA028131185A patent/CN1536988A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002344686B2 (en) | 2008-07-31 |
| US20040247643A1 (en) | 2004-12-09 |
| EP1411905A4 (en) | 2008-01-23 |
| CA2452075C (en) | 2012-08-14 |
| NZ529858A (en) | 2006-02-24 |
| WO2003009833A1 (en) | 2003-02-06 |
| AUPR602401A0 (en) | 2001-07-26 |
| CA2452075A1 (en) | 2003-02-06 |
| US8197839B2 (en) | 2012-06-12 |
| JP4913321B2 (ja) | 2012-04-11 |
| CN1536988A (zh) | 2004-10-13 |
| EP1411905A1 (en) | 2004-04-28 |
| JP2004535473A (ja) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2155124T3 (es) | Composiciones farmaceuticas liquidas a base de hormonas tiroideas. | |
| BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
| BRPI0611400B1 (pt) | formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas | |
| DE60105448D1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
| DE50211045D1 (de) | Medizinische aerosolformulierungen | |
| BR0212434A (pt) | Dispositivos médicos contendo análogos de rapamicina | |
| DE60220049D1 (de) | Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer | |
| ATE453427T1 (de) | Katheter zur modifizierung der formulierung von mitteln | |
| BR0215380A (pt) | Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo | |
| ATE274955T1 (de) | Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken | |
| EE05404B1 (et) | Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nhtud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| BR0210631A (pt) | Composição farmacêutica de liberação prolongada | |
| HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
| ATE272628T1 (de) | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen | |
| BR0309115A (pt) | Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco | |
| BRPI0414305A (pt) | sistema de liberação de drogas por via oral | |
| DE69716469D1 (de) | Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol | |
| BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
| BR0015225A (pt) | Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar | |
| BR0214159A (pt) | Sistema farmacêutico radiopaco de liberação prolongada | |
| DK1502586T3 (da) | Anvendelse af desinficerende midler ved fremstillingen af en farmaceutisk sammensætning til forebyggelsen eller behandlingen af inflammationer i det indre af menneskekroppen | |
| BR0015699A (pt) | Formulação de solução aquosa de alfa-interferon | |
| DE60320034D1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin | |
| EA200200914A1 (ru) | Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина | |
| YU39396A (sh) | Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: VIRBAC CORPORATION (US) Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 9/00 (2006.01), A61K 9/20 (2006.01), A61K 9/2 |